TRAILSTONE-GROUP
16.5.2023 08:01:33 CEST | Business Wire | Press release
Trailstone Group, a global energy and technology company, announced today that it has begun offering renewable energy risk management, asset optimization and trading services across Norway, Sweden, Denmark and Finland. The company can deploy a suite of renewable energy products including route to market Power Purchase Agreements (PPAs), imbalance risk management services and management of Guarantees of Origin (GoOs). Since 2013, Trailstone has provided similar services for more than 18,000 MW of renewable energy assets across the EU, UK and US, and recently began offering similar services in Japan.
An influx of new intermittent renewable power over the past five years has significantly increased complexity in Nordic power markets, and the Nordic region is projected to triple its wind and solar capacity by 2030. A number of market reforms will be implemented in 2023 and 2024 to support the continued development of renewables and more closely integrate Nord Pool with European power markets. Expected reforms include flow-based market coupling, the introduction of flexibility markets and the shift to 15-minute resolution in intraday markets. Trailstone has helped wind and solar asset owners and developers navigate similar market reforms across the globe and is well positioned to help asset owners in the Nordics minimize risk and optimize returns as Nord Pool markets evolve.
Ante Pogacic, Global Head of Power and Renewables at Trailstone said: “Nordic power markets are following a similar trend that we’ve helped clients navigate in other global markets as the world races to install more wind and solar generation. Renewable asset owners and developers selling power into Nord Pool need solutions such as our AI-enabled optimization platform to manage increasing market complexity, and we’re excited to extend our services and experience.”
For the past 30 years, hydropower has been the primary balancing tool in the Nordic power system due to its energy storage capacity and flexible generation. In the coming years, both the value of flexible hydropower and challenges for intermittent wind and solar generation will increase. In recent years with a poor hydrological balance, during which the Nordics receive lower than average precipitation, the achieved price for wind and solar production has been reduced in relation to the price of electricity. For example, analysis done by Trailstone found that in 2022, a year of lower than expected hydropower production, wind power owners in the Nordics achieved, on average, 70-75% of the market's power price and incurred significantly increased imbalance costs.
Geir Dvergastein, Market Manager, Norway, at Nord Pool said: “With market players such as Trailstone who can intelligently optimize the amount of wind and solar power available to the grid, we’re confident that we can implement the reforms needed to support the shift toward more intermittent renewable generation while still ensuring a reliable and efficient power supply."
Trailstone’s proprietary optimization platform uses robust weather models, data analytics and Artificial Intelligence (AI) to better predict renewable energy supply and optimize returns for asset owners. Trailstone’s experienced risk management and trading teams use the platform to manage imbalances caused by weather related production risks, lowering the barriers to entry for asset developers and enabling the deployment of more wind and solar generation. At the grid level, improving the effectiveness and efficiency with which renewables are managed enables more assets to connect to the grid, lowering reserve requirements and costs, all of which provide a better environment for the end consumer.
About Trailstone
Trailstone is a global renewable energy trading and asset management firm that provides risk management and energy optimization to improve production and financial returns. The company offers a fully automated end-to-end renewable power management platform, backed by a successful track record in energy trading. Trailstone’s proprietary technology leverages data analytics and meteorology to offer robust modeling, forecasting and trading capabilities to its clients. Trailstone was founded in April 2013. To date, Trailstone has helped optimize more than 18,000 MWs of renewable energy assets and operates in 20 countries. Learn more at www.trailstonegroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
